Thanks, Matt, and good day everyone. I'll begin with our view of the market environment. The Federal Reserve's interest rate hike campaign to tamp down inflation has begun to have its intended effect with tapering consumer prices that reached 40 year highs. However, inflation remains elevated and higher rates are putting downward pressure on loan demand, causing businesses to start to scale back on expansion plans in ways that could slow the economy enough to lead to a recession this year. On top of all that, the recent failures of Silicon Valley Bank, Signature Bank and First Republic along with the emergency sale of Credit Suisse in Europe could further tighten financial conditions, even if the Fed seizes interest rate hikes. In fact, according to Fed data, banks have already tightened their lending standards since the failures. This is important to monitor because U.S. regionally and community banks are major providers of capital, which could meaningfully weigh on economic activity. While we are predicting a severe recession or a material failure of the banking system, we think the events of the past quarter suggest that market volatility will continue and thus prudent credit investors with available capital will be well positioned. This creates potential growth catalyst for OCSL, we believe private credit funds may have significant and possibly long lasting opportunities to fill the lending gaps resulting from the bank's inability to meet demand. Ultimately, we believe the fallout from all of this will likely benefit those private lenders such as Oaktree that have sufficient scale to provide debt financing for large scale transactions and that aren't facing the types of problems that can result from [lax] (ph) due diligence. At OCSL, we have experience across all market cycles. And with strong capital and a long term perspective, the conviction needed to withstand short term volatility and continue to invest and generate strong returns for our shareholders. Our focus on relative value coupled with our ability to negotiate and structure customized deals that provide downside protection allows us to invest across multiple markets and issuers, with the ability to withstand the impact of a potentially deteriorating economic environment. And the successful completion of our LSI2 merger and the greater scale it created gives us a timely advantage. From where we sit today, we are confident in our abilities to further deploy capital on favorable terms and generate consistently strong returns for our shareholders. Now turning to the overall portfolio. At the close of the March quarter, our portfolio was well diversified with $3.2 billion at fair value across 165 companies, up from 146 a year earlier. We continue to emphasize larger and more diversified businesses that are better positioned to weather downturns or market turbulence. Median portfolio company EBITDA as of March 31 was approximately $133 million, up slightly from $128 million in the prior quarter. Leverage in our portfolio companies was relatively steady at 5.1 times, well below overall middle market leverage levels. The portfolio's weighted average interest coverage based on trailing 12 month performance declined slightly to 2.4 times from 2.5 times in the prior quarter due to rising base rates. Turning now to our origination activity, our $124 million of new investment commitments were spread over six new and three existing portfolio companies in the quarter. Let's look at a couple of representative examples. First, Oaktree originated a $160 million commitment to finance the merger of Whitcraft and Paradigm Precision, leading suppliers of machined and fabricated aerospace components and assemblies based in Connecticut. Two private equity sponsors sought to merge the two companies together to create a leading aviation engine components manufacturer, which would serve top companies such as GE and Rolls Royce, among others. This was a complex situation where our extensive aerospace industry knowledge and flexible investment approach allowed us to provide a solution to the sponsors. $12 million of this deal was allocated to OCSL to low those price favorably at SOFR plus 700 basis points with strong downside protections. Second, Oaktree originated a $100 million commitment to Harrow Health, a commercial stage eye care company with a current market cap of approximately $750 million. OCSL was allocated $11 million. The company is seeking capital to fund its growth energy by leveraging its unique positioning within the ophthalmology compounding space. This first lien deal was priced at SOFR plus 650 basis points with call protection and covenants. We also received warrants, which could provide upside and generate future capital gains. Looking ahead, our pipeline remains robust as we are evaluating a range of interesting investment opportunities that we believe present an attractive risk award. Turning to credit quality. As Matt mentioned, we moved two investments to non-accrual during the quarter. The first, in an investment that we made into SiO2 Materials Science, an advanced material sciences company that has invested in new technology for the packaging and containment of biological drugs and molecular diagnostics. The company made a significant investment to build up production capacity for the COVID back seen that has the global supply glut of COVID vaccines and as the pandemic receded, the company needed to pivot its business and reconfigure facilities for non-COVID demand, which is still strong, but off from peak levels. The best way for the company to right size its capital structure, which included several tranches junior to our first lien term loan [indiscernible] reorganization. Oaktree committed approximately $60 million of debt financing in addition to its initial $205 million loan to provide stability through expedited restructuring, while the company continues operations in its normal course of business. OCSL's total investment was marked at $50 million at quarter end, or approximately 88%% of par. We believe that we are well covered on the term loan and the debt given the collateral of the state of the art U.S. based manufacturing facility and proprietary IP of their unique packaging technology, which has an appeal to a wide variety of customers. We believe that SiO2 is well positioned for long term success. The second non-accrual event included an investment that we made in conjunction with Oaktree's real estate group in early 2021 to a luxury residential condominium developer in the San Francisco market. While we have received material repayments on our initial investment as units were sold over the course of the last two years, the recent rise in mortgage rates and the challenging environment for the technology industry has weighed on sentiment in the San Francisco market and has significantly pressured condo sales. In February, we did not extend our loan to the borrower and we have been in discussions about a modification of extension terms to facilitate the sale of the building by the sponsor. We believe that we are well covered on the loans and we put it on non-accrual status as the sponsor is working to sell the property. OCSL's total investment was marked at $23 million at quarter end or approximately 98% at par. Once again, as Matt noted, in both of these instances, the challenges involve company specific issues that we believe do not indicate broader credit issues within our portfolio and we expect to resolve each situation in the near term. In summary, our strong liquidity position and experience across various cycles coupled with the breadth of the Oaktree platform position OCSL very well for the second half of fiscal 2023. Now, I will turn the call over to Chris to discuss our financial results in more detail.